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A B S T R A C T
Erbium 169Er is one of the most interesting radiolanthanides for new potential receptor-targeted β− therapy
applications due to its low energy β− emissions, very low intensity ɣ rays and the possibility to use 68Ga or 44Sc
as companion for diagnostic in a theranostics approach. Currently it can be produced in reactors through the
neutron activation of highly enriched 168Er. The low specific activity of the produced carrier-added 169Er is
limiting its use for receptor-targeted therapy. Nonetheless it is used for radiosynoviorthesis of small joints. The
aim of this work is to develop a new large-scale production method for the supply of very high specific activity
169Er. Highly enriched 168Er target has been irradiated at ILL nuclear reactor and shipped to CERN-MEDICIS.
There, the irradiated sample has been mass separated in order to isolate 169Er from the high amount of remaining
stable 168Er. The proof of principle for a preclinical dose production has been demonstrated with a collection of
≈17MBq. The specific activity obtained was ≈240 GBq/mg (≈200 times higher than the product obtained at
End of Bombardment – EOB) and the overall separation efficiency was ≈0.2%. Several improvements for the
future have been identified and are promising. One of them is the installation of the new laser laboratory at
CERN-MEDICIS that will allow to improve the selective ionization of erbium atoms leading to an increase of the
efficiency of the method. This method can provide the supply of high specific activity 168Er, first for preclinical
studies, and opens also the potential for future large-scale supply.
1. Introduction
Erbium 169Er is one of the most interesting radiolanthanides for new
potential receptor-targeted β− therapy applications. Its main physical
characteristics (see Table 1) are low energy β− emissions and the near
absence of ɣ rays. This is an advantage for dosimetry and radio-
protection as well as for limiting damage to healthy tissues further
away. The low energy β-emissions can diversify the applications al-
lowing 169Er to be suitable for tumors not efficiently treatable with
higher energies β− emissions. In Table 1 are resumed the main physical
properties of 169Er compared to the actual β− emitter of reference
177Lu, currently used for commercially available radiopharmaceuticals
for treatment of neuroendocrine tumors [1].
As it is a trivalent element, it can be used with the same chelators as
those used for coupling the diagnostic counterparts such as 68Ga or
44Sc, and thus easily be used for theranostics applications. Due to its
characteristics, it has already been used in medicine for radio-
synovectomy (also called radiosynoviorthesis) of small joints such as
finger joints [3]. Radiosynoviorthesis has been used since 1952 with the
injection of radiopharmaceuticals based on pure or dominant β−
emitters. Different isotopes are currently used for different sized joints
depending on their physical characteristics, in particular the electron
energy emission (higher β− energy for larger sizes of the treated joint):
90Y is used for knee joints, while 186Re is used for elbow and ankle
joints. For those applications, the radionuclides are used as a colloid in
citrate form [3] and low specific activity is sufficient, thus carrier-added
169Er can be used. The radionuclide batches are currently produced in
nuclear reactors irradiating highly enriched (up to 98.2%) 168Er targets.
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The neutron capture reaction 168Er(n,γ)169Er has a rather small cross
section, namely 2.3 barns for thermal neutrons. This is limiting the
specific activity. Considering a neutron flux of 1.2·1015 n/cm−2 s−1,
available in a high-flux nuclear reactor such as that of Institut Laue-
Langevin (ILL) in Grenoble, and ten days of irradiation, a specific ac-
tivity of ≈5GBq/mg can be achieved. Still, this corresponds to a ratio
between 168Er and 169Er nuclides of 600:1 at end of irradiation and even
higher at the time of use. The dilution of 169Er in stable erbium limits
the benefits in receptor-targeted therapies as stable erbium isotopes will
compete with the radioactive one for the radiolabeling. Consequently,
only a small fraction of the targeting vectors would carry “useful”
radioactive 169Er while all others would just carry “cold” stable Er that
is not therapeutically active. Therefore, higher specific activities are
required. The theoretical specific activity of pure non-carrier-added
169Er would correspond to 3 TBq/mg. It is defined as the activity of
169Er over its mass, corresponding to the ideal scenario where only pure
169Er is present.
For improving the specific activity, 169Er should be separated from
stable erbium 168Er. As they are isotopes of the same element, con-
ventional chemical separation processes are not beneficial. In the pre-
sent work the use of EMIS technology (ElectroMagnetic Isotope
Separation) for a reactor irradiated enriched 168Er target is studied. This
will allow producing very high specific activity batches of 169Er for the
potential application in vectorized radiotherapy. The experiments have
been performed combining irradiations at ILL’s high flux nuclear re-
actor in Grenoble with the mass separation of the irradiated samples at
CERN-MEDICIS [5]. The experimental campaign results are shown and
future improvements of the system are discussed.
2. Experimental method
2.1. Off-line separation of stable erbium
The first step was to determine the experimental overall efficiency
of stable erbium extraction, ionization and mass separation. This allows
determining extrapolated yield values for production estimations. The
separation of a known mass of stable erbium was performed in the off-
line laboratory at CERN. For this experiment MEDICIS target unit #631-
M, the one dedicated to the following separation of 169Er at CERN-
MEDICIS, was used. It consists in a conventional ISOLDE type target
unit, with inside an empty target container and a tungsten surface ion
source. Usually a tantalum plug is used to close the tantalum target
container, but with the high operation temperatures this risk getting
diffusion-bonded. This behavior is fine when the target is irradiated
with CERN’s proton beam because the target container has not to be
opened after use. In our case as the target container has to be filled
several times, the plug should be easily removable. Therefore, for
guaranteeing the retrieval of the inserted samples a graphite plug has
been used.
The inserted sample was prepared from erbium plasma standard
solution (1mg/ml in 5% HNO3, Specpure, Alfa Aesar). Natural Erbium
is composed of 6 stable isotopes among which 166Er is the most abun-
dant, 33.5%. This isotope was followed during our “cold” tests. An
aliquot of 100 µl, corresponding to 3.6 1017 atoms of natural erbium,
was poured on a graphite disc placed on a molybdenum boat. The boat
prevents any direct contact between the sample and the tantalum
container to avoid reactions of graphite and tantalum at high tem-
perature. By means of a lamp, the sample was heated to evaporate the
acid solution and deposit the erbium salt Er(NO3)3. In the Fig. 1 the
preparation of the sample is shown.
Then the sample was loaded into the target container. After vacuum
pumping the target container was heated to ≈2100 °C. The extraction
was performed over 7.8 h collecting 3.15 1014 positively charged ions
of 166Er. As the initial number of 166Er atoms in the sample was
=3.6 10 0.335 1.21 1017 17, the overall efficiency of the mass se-
paration was =100 0.26%3.15 101.21 10
14
17 . When reaching the maximum
temperature in the target, the Er+ current on mass 166 peaked at
1.7 nA. Then as the temperature remained constant until the end of the
measurement the release of 166Er from the target exponentially de-
creased over time as expected. Nevertheless, once the target was re-
moved from the oven, we noticed molybdenum boat damages on the
contact points between the boat and the graphite. For this reason, fol-
lowing theoretical and experimental considerations, rhenium was
chosen as future boat material.
This test showed the feasibility of erbium extraction and laid the
basis for the radioactive experiment.
2.2. Off-line separation of radioactive erbium
A quartz ampoule was filled with (7 ± 0.1) mg of Er2O3 powder
enriched to 98.2% in 168Er and irradiated for 6.5 days at the high-flux
reactor of ILL in a neutron flux of 1.2 1015 n.cm−2 s−1 leading to a
calculated specific activity of 3.7 GBq/mg. Then the radioactive sample
was shipped to CERN where it was put inside one of MEDICIS fume
hoods. The ampoule was opened and the erbium oxide was dissolved
within 3ml of 1M HNO3. The solution was then transferred from the
ampoule to the support consisting in a graphite holder inserted in a
rhenium boat (Fig. 2).
Then as in the test experiment, the solution was heated to around
40 °C to evaporate the solution to dryness on the holder. The sample
was then inserted inside the MEDICIS target unit (#631-M), which was
later positioned on the mass separator front end (Fig. 3). This operation
did not lead to a significant radiation dose of the operators since 169Er
Table 1
Main physical properties comparison between 169Er and 177Lu (data are ex-
tracted from NuDat 2 [2].
Radioisotope 169Er 177Lu
Half-life (days) 9.39 6.65









Mean/maximum penetration in soft tissues 0.2/1 mm [3] 0.23/1.7mm [4]
Fig. 1. Erbium sample used for the offline erbium separation efficiency mea-
surements.
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has very low ɣ emission. As before the target and ion source unit was
then pumped to vacuum. After bringing the ion source to the operation
temperature, the target was slowly heated to release the Er. The Er ions
were mass-separated and the 169Er was implanted into zinc coated gold
foils (Fig. 4).
3. Results
The collection lasted 24 h. The operating temperature was around
2000–2100 °C both in the target container and the surface ion source.
The readout of the current from the collection foils was in agreement
with the Faraday cup measurements upstream and the collimator
readout. The losses in the collimator were almost constant all along the
collection oscillating around 7%. The total ion current of 169Er and its
isobaric contaminants peaked at 3.8 nA when the target container
reached the maximum temperature, then the signal decreased ex-
ponentially as expected. The number of atoms collected was 2.56 1014.
The ɣ spectrometry analysis showed that 17(6) MBq of 169Er1 and 10(4)
kBq of 169Yb had been collected on the zinc coated gold foil. This
corresponds to 2 1013 169Er atoms and 4 1010 169Yb atoms. The
difference between the integrated current and the detected activities is
assumed to correspond to a tail of stable 168Er ions. At the time of the
separation the quantity of 168Er was 2 103 times higher compared to
169Er (calculated specific activity of ≈1.3 GBq/mg). Therefore, a small
part of the tail of the beam profile at mass 168 can be found on one side
of the Gaussian profile of the mass 169 beam. The mass separation
improved the ratio of 168Er to 169Er from≈2000:1 to ≈10:1, meaning a
gain of a factor 200. Correspondingly the specific activity was increased
from ≈1.3 GBq/mg to ≈240 GBq/mg, closer to the desired specific
activity for a potential clinical receptor-targeted radiotherapy applica-
tion. These results should be confirmed through an ICP-MS measure-
ment after complete decay of the radionuclides. However, only
≈17MBq of 169Er were extracted from the ≈9GBq of 169Er present in
the MEDICIS target container before mass separation. The overall effi-
ciency was consequently ≈0.2% close to the value obtained during the
off-line test with stable erbium.
The described experiment represents the first production of high
specific activity 169Er. The proof of principle of the production of a
usable dose was performed. Nevertheless, the production yield and the
quality of the product can be improved. The simplest improvement is
the reduction of the residual 168Er content, which can be achieved
optimizing the position of the mass separator slit. The optimal position
for the maximum reduction of stable erbium minimizing the 169Er
should be found. A more important improvement is needed to increase
the overall efficiency, as 0.2% is too low for practical purposes. A much
higher ionization efficiency can be expected when replacing surface
ionization by resonant laser ionization.
4. Resonant laser ionization
The installation of lasers has not yet been completed at the MEDICIS
facility [6]. Therefore, the experiments have been performed at Jo-
hannes Gutenberg University of Mainz, using the RISIKO mass se-
parator [7]. The tests have been performed with stable erbium.
An erbium plasma standard solution (1mg/ml in 5% of HNO3,
Specpure, Alfa Aesar), was diluted by a factor of ten. 3 µl of the diluted
erbium solution were deposited on a zirconium foil and dried by a heat
lamp. The 3 µl of erbium correspond to 1.08 1015 erbium atoms. For
this experiment a two-step scheme has been selected that had been
previously developed by the LARISSA group [8]. The full analysis of
this experiment will be presented in a separate paper.
In Fig. 5 an example of a mass spectrum is presented. The laser On/
Off enhancement ratio ranged from ≈1000 to ≈10,000 during the
main part of the ion extraction. As expected all the laser ionized erbium
was observed as atomic ions, no laser enhancement was observed for
erbium oxide ions. The significant presence of atomic gadolinium and
gadolinium oxide did not interfere with the measurement of the erbium
separation efficiency. Indeed, its atomic masses range from 152 to 160
and the oxides from 168 to 176, while the erbium measurement was
performed on mass 166.
5. Discussion and future perspectives
169Er is an interesting isotope for receptor-targeted radiotherapy
due to its physical and chemical characteristics. However, it is not
currently available with a sufficient specific activity because of the
Fig. 2. Graphite holder used for the 169Er separation. The erbium solution has
been poured inside and evaporated to have a deposit on the graphite.
Fig. 3. MEDICIS target unit positioned on the mass separator front end for the
169Er collection.
Fig. 4. Collection foils used. Backside view of the foils facing each a 10mm
diameter collimator. The Zn coating is on the opposite side.
1 The large uncertainty in the activity determination results from the inter-
ference correction in the ɣ ray analysis. All ɣ rays populated in 169Er decay are
also populated with much higher intensity in the 169Yb decay. Thus, despite the
much lower 169Yb activity, it actually dominates the ɣ ray spectra and 169Er is
only observed as increment at certain energies.
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quite small cross section (2.3b) for the neutron activation reaction of
168Er. This leads to a strong dilution of radioactive 169Er by stable 168Er.
The combination of irradiation in a high-flux nuclear reactor with
electromagnetic mass separation is proposed to overcome this issue.
The proof-of-principle experiments performed at the ILL reactor and the
CERN-MEDICIS facility showed the feasibility of this production
method. The specific activity could be improved from ≈1.3 GBq/mg to
≈240 GBq/mg. This was the first production of high specific activity
169Er and ≈17MBq of mass-separated 169Er were obtained. However,
the overall efficiency was only 0.2%. Boosting this number by resonant
laser ionization was studied at JGU Mainz using the RISIKO mass se-
parator. The finalization of the MELISSA laser laboratory at CERN-
MEDICIS in the first half of 2019 will allow verifying the experimental
gain factor in the production yields of 169Er.
This work has demonstrated that 169Er can be produced at high
specific activities and be available for preclinical studies. Preclinical
trials could be performed starting from 2019. In parallel, the above-
mentioned improvements will allow soon to get much higher activity
making 169Er available for receptor-targeted radiotherapy clinical trials.
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